BCAL Diagnostics Limited (ASX:BDX) Insider Jayne Shaw Buys 725,000 Shares

BCAL Diagnostics Limited (ASX:BDXGet Free Report) insider Jayne Shaw bought 725,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average cost of A$0.11 ($0.07) per share, with a total value of A$76,850.00 ($50,894.04).

BCAL Diagnostics Stock Performance

The company has a quick ratio of 6.70, a current ratio of 5.21 and a debt-to-equity ratio of 24.77.

BCAL Diagnostics Company Profile

(Get Free Report)

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body.

Featured Articles

Receive News & Ratings for BCAL Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BCAL Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.